American Journal of Food Science and Health
Articles Information
American Journal of Food Science and Health, Vol.2, No.6, Dec. 2016, Pub. Date: Jan. 9, 2017
Effect of Heat-Killed Lactobacillus johnsonii No. 1088 on Gastroesophageal Reflux Disease-Related Symptoms: A Pilot Clinical Study
Pages: 176-185 Views: 24101 Downloads: 804
[01] Yasuhiko Komatsu, Snowden Co., Ltd., Chiyoda-ku, Tokyo, Japan.
[02] Tomoya Sasaki, Snowden Co., Ltd., Chiyoda-ku, Tokyo, Japan.
[03] Masami Ohishi, Snowden Co., Ltd., Chiyoda-ku, Tokyo, Japan.
To evaluate the efficacy of orally administered heat-killed Lactobacillus johnsonii No. 1088 (HK-LJ88) on gastroesophageal reflux disease (GERD)-related symptoms and its safety aspects, we conducted a single-blind clinical study comprising 2 dose groups (about 109 and 1010 cells/day). Thirty healthy volunteers including subjects feeling slight stomach uneasiness (22 males and 8 females), aged 24-67, not receiving medical treatment for gastric diseases and not taking drugs for gastrointestinal care, were randomly allocated 1:1 to low- or high-dose group, and instructed to ingest HK-LJ88 for 6 weeks. GERD-related symptoms were evaluated by use of the “frequency scale for the symptoms of GERD” (FSSG) and found to be significantly improved after 6 weeks in both groups. Although no significant decrease in serum gastrin concentration was observed in either group as a whole, the gastrin concentration of 7 subjects who had answered that his/her stomach condition had been improved without worsening, significantly decreased after 6 weeks. Regarding safety aspects, blood biochemical, blood cellular, and urinary tests did not show any worsening signs. Fourteen subjects experienced mild and temporal unwellness, but recovered soon. One subject in the low-dose group felt discomfort in the stomach and esophagus and voluntarily discontinued the study. This subject, however, declared afterward the tendency to feel uneasy after ingesting fermented dairy foods, which uneasiness might have reflected food allergy to lactic acid bacteria. Taken together these results suggest that ingestion of HK-LJ88 was effective to improve GERD-related symptoms of healthy volunteers, and was well tolerated up to 1010 cells/day.
Lactic Acid Bacteria, Gastroesophageal Reflux Disease (GERD), Gastrin, Frequency Scale for the Symptoms of GERD (FSSG), Lactobacillus johnsonii No. 1088
[01] Kahrilas P. J., Shaheen N. J., Vaezi M. F., Hiltz S. W., Black E., Modlin I. M., Johnson S. P., Allen J., Brill J. V. (2008). American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 135 (4): 1383-1391.
[02] Garnock-Jones K. P. (2015). Vonoprazan: first global approval. Drugs. 75 (4): 439-443.
[03] Ashida K., Sakurai Y., Nishimura A., Kudou K., Hiramatsu N., Umegaki E., Iwakiri K., Chiba T. (2015). Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 42 (6): 685-695.
[04] Ashida K., Sakurai Y., Hori T., Kudou K., Nishimura A., Hiramatsu N., Umegaki E., Iwakiri K. (2016). Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 43 (2): 240-251.
[05] Fossmark R., Johnsen G., Johanessen E., Waldum H. L. (2005). Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 21 (2): 149-154.
[06] Waldum H. L., Arnestad J. S., Brenna E., Eide I., Syversen U., Sandvik A. K. (1996). Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut. 39 (5): 649-653.
[07] Aiba Y., Nakano Y., Koga Y., Takahashi K., Komatsu Y. (2015). A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiology Open. 4: 465-474.
[08] Komatsu Y., Aiba Y., Nakano Y., Koga Y. Probiotics, prebiotics, and biogenics for the stomach. In: Rao V, Rao LG, editors. Prebiotics and Probiotics in Human Nutrition and Health. Rijeka, Croatia: InTech; 2016. p. 363-381.
[09] Kusano M., Shimoyama Y., Sugimoto S., Kawamura O., Maeda M., Minashi K., Kuribayashi S., Higuchi T., Zai H., Ino K., Horikoshi T., Sugiyama T., Toki M., Ohwada T., Mori M. (2004). Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 39 (9): 888-891.
[10] Kusano M., Shimoyama Y., Kawamura O., Maeda M., Kuribayashi S., Nagoshi A., Zai H., Moki F., Horikoshi T., Toki M., Sugimoto S., Mori M. (2007). Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. Dig Dis Sci. 52 (7): 1673-1677.
[11] Nonaka T., Kessoku T., Ogawa Y., Yanagisawa S., Shiba T., Sakaguchi T., Atsukawa K., Takahashi H., Sekino Y., Iida H., Endo H., Sakamoto Y., Koide T., Takahashi H., Yoneda M., Maeda S., Nakajima A., Gotoh E., Inamori M. (2013). Comparative Study of 2 Different Questionnaires in Japanese Patients: The Quality of Life and Utility Evaluation Survey Technology Questionnaire (QUEST) Versus the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease Questionnaire (FSSG). J Neurogastroenterol Motil. 19 (1): 54-60.
[12] R_Core_Team. (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria URL https://wwwR-projectorg/.
[13] Fukushima Y., Yamano T., Kusano A., Takada M., Amano M., Iino H. (2004). Effect of fermented milk containing Lactobacillus johnsonii La1 (LC1) on defecation in healthy Japanese adults ---- A double blind placebo controlled study ----. Bioscience Microflora. 23 (4): 139-147.
[14] Felley C. P., Corthesy-Theulaz I., Rivero J. L., Sipponen P., Kaufmann M., Bauerfeind P., Wiesel P. H., Brassart D., Pfeifer A., Blum A. L., Michetti P. (2001). Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 13 (1): 25-29.
[15] Michetti P., Dorta G., Wiesel P. H., Brassart D., Verdu E., Herranz M., Felley C., Porta N., Rouvet M., Blum A. L., Corthesy-Theulaz I. (1999). Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion. 60 (3): 203-209.
[16] Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. (2001). Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 47 (5): 709-710.
[17] Fujimura S., Kato S., Oda M., Miyahara M., Ito Y., Kimura K., Kawamura T., Ohnuma M., Tateno H., Watanabe A. (2006). Detection of Lactobacillus gasseri OLL2716 strain administered with yogurt drink in gastric mucus layer in humans. Lett Appl Microbiol. 43 (5): 578-581.
[18] Kato-Mori Y., Orihashi T., Kanai Y., Sato M., Sera K., Hagiwara K. (2010). Fermentation metabolites from Lactobacillus gasseri and Propionibacterium freudenreichii exert bacteriocidal effects in mice. J Med Food. 13 (6): 1460-1467.
[19] Takagi A., Yanagi H., Ozawa H., Uemura N., Nakajima S., Inoue K., Kawai T., Ohtsu T., Koga Y. (2016). Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. Gastroenterol Res Pract. 2016: 7490452.
[20] Uchida M., Shimizu K., Kurakazu K. (2010). Yogurt containing Lactobacillus gasseri OLL 2716 (LG21 yogurt) accelerated the healing of acetic acid-induced gastric ulcer in rats. Biosci Biotechnol Biochem. 74 (9): 1891-1894.
[21] Nagaoka M., Hashimoto S., Watanabe T., Yokokura T., Mori Y. (1994). Anti-ulcer effects of lactic acid bacteria and their cell wall polysaccharides. Biol Pharm Bull. 17 (8): 1012-1017.
[22] Gomi A., Harima-Mizusawa N., Shibahara-Sone H., Kano M., Miyazaki K., Ishikawa F. (2013). Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J Dairy Sci. 96 (2): 832-837.
[23] Shirasawa Y., Shibahara-Sone H., Iino T., Ishikawa F. (2010). Bifidobacterium bifidum BF-1 suppresses Helicobacter pylori-induced genes in human epithelial cells. J Dairy Sci. 93 (10): 4526-4534.
[24] Gomi A., Iino T., Nonaka C., Miyazaki K., Ishikawa F. (2015). Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults. J Dairy Sci. 98 (4): 2277-2283.
MA 02210, USA
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - American Institute of Science except certain content provided by third parties.